PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA

NCT04015622 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Interventions

DRUG: Enzalutamide
DRUG: Docetaxel

Sponsor

British Columbia Cancer Agency